- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04520698
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease (UPLIFT-AD)
The purpose of this study is to evaluate a comprehensive model for integrating both primary and specialty Palliative Care for older adults with dementia into nursing facilities. Palliative Care is a supportive care approach that aims to improve the quality of life of patients and their families facing serious or life-threatening illnesses, through the prevention and relief of suffering through the treatment of pain and other problems, using physical, psychosocial and spiritual approaches. Palliative care is specialized medical care for people who are living with a serious illness. This type of care is focused on providing relief from the symptoms and from the stress of the illness. The goal is to improve quality of life for both patient and family.
The UPLIFT-AD model will include providing education on primary Palliative Care for residents with dementia to nursing facility staff, training nursing facility staff in providing primary Palliative Care, and providing access to specialty Palliative Care consultations for residents. To help understand the impact of these interventions, this study will also collect information about resident health, the care they receive, and perceptions of their quality of life according to both family members and nursing facility staff.
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Alex Floyd
- Phone Number: (317) 274-9164
- Email: acfloyd@regenstrief.org
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46201
- Recruiting
- American Senior Communities
-
Contact:
- Alex C Floyd, BS
- Phone Number: 317-274-9164
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
-
NURSING HOME RESIDENTS:
- Long-stay resident in an enrolled nursing home defined as not paying through Medicare Part A at the enrolled facility.
- Has a diagnosis of moderate to severe ADRD, as measured on the Minimum Data Set (MDS)
- Length of stay >30 days
FAMILY MEMBERS/SURROGATE DECISION MAKERS:
- Family member and/or surrogate decision maker for an eligible resident in an enrolled nursing home
- English-speaking
NURSING HOME STAFF:
- Staff, nurse, or nurse assistant in an enrolled nursing facility
- English-speaking
Exclusion Criteria:
-
NURSING HOME RESIDENTS:
• Short-stay resident, defined as paying through Medicare Part A at the enrolled facility and/or receiving respite care
FAMILY MEMBERS/SURROGATE DECISION MAKERS:
• Non-English-speaking
NURSING FACILITY STAFF:
• Non-English-speaking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Usual Care
|
|
Experimental: Nursing Home-level UPLIFT-AD intervention
The UPLIFT-AD intervention consists of three major components delivered at the level of the nursing home: 1) in-house PC champions trained to a) facilitate advance care planning conversations with residents with Alzheimer's Disease and Related Dementias and their surrogate decision-makers, b) screen and follow up on residents' Palliative Care needs and c) serve as a liaison to Palliative Care consultants; 2) specialty Palliative Care consultant support providing individual consults for residents with complex Palliative Care needs; and 3) education on primary Palliative Care offered to all clinical NH staff.
|
Access to palliative care needs screening, advance care planning conversations, palliative care consultations
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in End-of-Life Dementia - Comfort Assessment In Dying scale (EOLD-CAD)
Time Frame: 1, 6, 12, and 18 months
|
The EOLD-CAD items assess the following 14 symptoms and conditions during the last 7 days of life: discomfort, pain, restlessness, shortness of breath, choking, gurgling, difficulty in swallowing, fear, anxiety, crying, moaning, serenity, peace, and calm.
These signs are assessed on a scale ranging from 1 to 3 as follows: not at all, somewhat, and a lot.
The last 3 items are reverse-coded because they are considered good conditions.
The CAD-EOLD score is constructed by summing the value of each item, and the total score ranges from 14 to 42 with higher scores indicating better symptom control.
|
1, 6, 12, and 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in End of Life Dementia - Satisfaction with Care (EOLD-SWC) scale
Time Frame: 6, 12, and 18 months
|
The EOLD-SWC assesses satisfaction with care during the prior 7 days.
The EOLD-SWC has 10 items, each measured on a 4-point Likert scale ranging from 1 to 4 as follows: strongly disagree, disagree, agree, strongly agree.
The questionnaire items address decision-making, communication with health care professionals, understanding the resident's condition, and the resident's medical and nursing care.
The total EOLD-SWC score represents a summation of all 10 items (range, 10-40), with higher scores indicating more satisfaction.
|
6, 12, and 18 months
|
Change in Single item quality-of-life (QOL) measure
Time Frame: 1, 6, 12, and 18 months
|
The single item quality-of-life measure is a seven point scale describing overall quality of life.
Lower scores indicate poorer quality of life.
|
1, 6, 12, and 18 months
|
Change in staff perceptions survey
Time Frame: 6, 12, and 18 months
|
Change in staff perceptions surrounding impact, adoption, and buy-in to the intervention will be assessed using a two-item survey that asks about the perceived helpfulness of interactions and materials provided to residents and families.
|
6, 12, and 18 months
|
Change in Palliative Care outcomes
Time Frame: 1, 3, 6, 9, 12, 15, and 18 months
|
Change in nursing home-level palliative care outcomes will be assessed using abstraction from the Minimum Data Set, and include measures of resident mood, pain and symptom management, hospice use, goals of care, and palliative care service use.
|
1, 3, 6, 9, 12, 15, and 18 months
|
Change in staff palliative care knowledge
Time Frame: 5 and 7 months
|
Change in staff palliative care knowledge will be measured by the Palliative Care survey (PCS).
The PCS is a validated instrument, which includes subscales evaluating the frequency of key PC practice behaviors: family communication, provider coordination, planning/intervention, and bereavement.
The total instrument score and each of the subscales are averaged to produce a range from 1 to 4, with higher scores indicating superior PC practices.
|
5 and 7 months
|
Quality of Dying in Long Term Care (QOD-LTC)
Time Frame: 18 months
|
The quality of dying-long-term care (QOD-LTC) was developed for cognitively impaired and intact residents in NHs and residential care/assisted living settings [21].
It assesses perspectives on quality of personhood, closure, and preparatory tasks.
Higher mean scores reflect a higher quality of end-of-life in LTC.
|
18 months
|
Fidelity to intervention
Time Frame: 1, 6, 12, and 18 months
|
The UPLIFT fidelity checklist evaluates whether core components of UPLIFT have been sufficiently implemented at both the facility and resident level.
Facility level components include: receipt of staff training; establishment of a facility tailored UPLIFT protocol manual; identification of at least two in-house champions; assigned external PC consultants.
|
1, 6, 12, and 18 months
|
Change in Family Distress in Advanced Dementia Scale.
Time Frame: 6, 12, and 18 months
|
The Family Distress in Advanced Dementia Scale was developed for use with family members of nursing home residents with advanced dementia.
This 21-item scale consists of three domains of distress: emotional distress, dementia preparedness, and nursing home relations.
Higher scores indicate higher distress.
|
6, 12, and 18 months
|
Change in End of Life Dementia - Symptom Management Scale.
Time Frame: 1, 6, 12, and 18 months
|
This scale examines the frequency a resident experiences nine symptoms a during the previous 7 days: pain, shortness of breath, depression, fear, anxiety, agitation, calm, skin breakdown, and resistance to care.
Frequency is assessed using a 6-point Likert scale ranging from 0 to 5: daily, several days a week, once a week, 2 or 3 days a month, once a month, never.
The EOLD-SM score ranges from 0-45 with higher scores indicating better symptom control (comfort).
|
1, 6, 12, and 18 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kathleen T Unroe, MD, MHA, Indiana University
- Principal Investigator: John Cagle, PhD, MSW, University of Maryland, Baltimore
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2005967061
- R01AG066922 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on UPLIFT-AD
-
Morehouse School of MedicineEmory UniversityCompletedEpilepsy | Depressive Symptoms | Anxiety Disorders and SymptomsUnited States
-
Boise State UniversityNot yet recruitingSubstance Use | Perinatal Depression | Perinatal Anxiety | Telehealth
-
Dartmouth-Hitchcock Medical CenterCompletedDepression | Non-Epileptic Seizure | Psychogenic Non-Epileptic Seizure | Psychogenic SeizureUnited States
-
Emory UniversityThe University of Texas Health Science Center, Houston; National Institute... and other collaboratorsCompletedDepression | Epilepsy | Depressive Symptoms | Seizure DisorderUnited States
-
Duke UniversityCompletedSubstance Use | Mental HealthUnited States
-
NYU Langone HealthCompletedHypertensionUnited States
-
Virginia Commonwealth UniversityJohns Hopkins University; University of Michigan; Boston Children's Hospital; Emory... and other collaboratorsCompletedDepression | Anxiety | Cystic FibrosisUnited States
-
University of UtahNational Institute of Nursing Research (NINR)CompletedPerinatal DepressionUnited States
-
Addpharma Inc.CompletedHypertensionKorea, Republic of
-
Addpharma Inc.Recruiting